tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Resmed (RMD) and Merck & Company (MRK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODDResearch Report), Resmed (RMDResearch Report) and Merck & Company (MRKResearch Report).

Insulet (PODD)

J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Insulet yesterday and set a price target of $300.00. The company’s shares closed last Friday at $255.55.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 7.9% and a 48.4% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Integra Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet with a $275.92 average price target, a 13.1% upside from current levels. In a report issued on October 18, Canaccord Genuity also maintained a Buy rating on the stock with a $290.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Resmed (RMD)

J.P. Morgan analyst David Low maintained a Hold rating on Resmed on October 28 and set a price target of $245.00. The company’s shares closed last Friday at $218.73.

According to TipRanks.com, Low is a 2-star analyst with an average return of 0.4% and a 50.0% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Nanosonics Limited, and Cochlear Limited.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $250.86 average price target, implying a 16.6% upside from current levels. In a report issued on October 28, Citigroup also downgraded the stock to Hold.

Merck & Company (MRK)

In a report issued on October 27, Chris Schott from J.P. Morgan maintained a Buy rating on Merck & Company, with a price target of $115.00. The company’s shares closed last Friday at $100.77, close to its 52-week high of $101.50.

According to TipRanks.com, Schott is a 2-star analyst with an average return of -0.5% and a 50.4% success rate. Schott covers the Healthcare sector, focusing on stocks such as Horizon Therapeutics, Idexx Laboratories, and Gilead Sciences.

Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $107.62, representing a 7.4% upside. In a report issued on October 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $120.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PODD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles